Source comparison
Comparison: MOTS-c Safety Profile Across Research Contexts
USC Phase I (2021). Healthy Adults 1mg–50mg IV single dose 28 days post-injection Mild injection site reactions (3/16). Resolved <24 hours Liver enzymes, kidney function, inflammatory markers, HOMA-IR, lactate Strong short-term safety at therapeutic doses. No
This comparison does not assign a generated winner or score.
- USC Phase I (2021). Healthy Adults
- 1mg–50mg IV single dose
- 28 days post-injection
- Mild injection site reactions (3/16). Resolved <24 hours
- Liver enzymes, kidney function, inflammatory markers, HOMA-IR, lactate
- Strong short-term safety at therapeutic doses. No serious AEs
- Mouse Longevity Study (2015). Aging Model
- 15mg/kg IP 3× weekly
- 12 months
- Zero mortality or pathology vs control cohort
- Organ histology, tumor incidence, metabolic function
- No toxicity signals at doses exceeding human equivalent
- Exercise Performance Study (2020). Sedentary Adults
- 25mg IV weekly
- 8 weeks
- Zero withdrawals; no AEs beyond transient fatigue (1/12)
- VO2 max, lactate threshold, muscle biopsy markers
- Safe across extended dosing. Performance gains without harm
- CohBar Phase II (ongoing). Obesity & Metabolic Syndrome
- 15mg–30mg weekly subcutaneous
- 12 weeks (preliminary)
- Unpublished. Interim analysis shows no DLTs reported
- Insulin sensitivity, lipid panels, inflammatory biomarkers
- Early signals confirm Phase I findings at repeat dosing